ClearPoint Neuro Q2 revenue record $6.0M (+14% YoY); biologics growth 40%; reaffirms FY guide $25-27M

ClearPoint Neuro, Inc.

2023-Q2 EPS reported -$0.52 revenue$11,383,000

Record Q2 revenue $6.0M, up 14% YoY; biologics & drug delivery revenue $3.4M (+40%).
Gross margin fell to 53% from 63% due to lower-margin preclinical services and facility transition costs.
Operating expenses rose to $10.3M from $7.5M on higher headcount, stock comp, and product development.
Cash & equivalents $26.5M at June 30, down from $37.5M at Dec 2022; operating cash burn $10.8M.
Reaffirmed FY2023 revenue guidance $25-27M; CEO outlines five key milestones for H2.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

ClearPoint Neuro, Inc. reported second quarter ended June 30, 2023 results: revenue record quarterly revenue of $6.0 million. Guidance reaffirmed.

Period: second quarter ended June 30, 2023
Revenue: record quarterly revenue of $6.0 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

and delivery to the brain, today announced financial results for its second quarter ended June 30, 2023. Second Quarter Highlights • Reported record quarterly revenue of $6.0 million, a 14% year-over-year increase; • Increased biologics and drug delivery revenue to $3.4 million, a 40% year-over-year increase; • Announced an example of a milestone-based

View on SEC.gov

Browse all earnings releases →

ClearPoint Neuro, Inc. filing history →

Source: SEC EDGAR

accession 0001285550-23-000096

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.